Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Cerecor Inc (CERC) USD0.001

Sell:$1.91 Buy:$2.22 Change: $0.04 (1.87%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Change: $0.04 (1.87%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
Change: $0.04 (1.87%)
Market closed |  Prices as at close on 3 April 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.

Contact details

540 Gaither Rd Ste 400
United States
+1 (410) 5228707

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$123.28 million
Shares in issue:
57.61 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Simon Pedder
    Executive Chairman of the Board
  • Michael Cola
    Chief Executive Officer, Director
  • Joseph Miller
    Chief Financial Officer, Principal Executive Officer and Principal Financial Officer
  • Jamie Harrell
    Executive Vice President - Marketing, External Communications
  • Pericles Calias
    Chief Scientific Officer and Head of Research & Development
  • Patrick Crutcher
    Chief Strategy Officer
  • Garry Neil
    Chief Medical Officer
  • Matthew Phillips
    Chief Commercial Officer
  • Jeff Wilkins
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.